

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 123439		APPLICATION NO. 10/530,568	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) Eric ADRIAENSSENS et al.			
				FILING DATE April 7, 2005		GROUP 1642	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Name			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation	
OTHER DOCUMENTS							
Examiner Initials	Cite No.	Including name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	1.	Cramer et al., "Nerve Growth Factor in Medullary Carcinoma of the Thyroid", Human Pathology, Vol. 10, No. 6, pp. 731-736, November 1979.					
	2.	Goretzki, M.D., R. A., "Nerve Growth Factor (NGF) Sensitizes Human Medullary Thyroid Carcinoma (hMTC) Cells for Cytostatic Therapy In Vitro", Surgery, pp. 1035-1042, December 1987.					
	3.	Moley et al., "Oncogene and Growth Factor Expression in MEN 2 and Related Tumors", Henry Ford Hosp. Med. Journal, Vol. 40, No. 3 & 4, pp. 284-288, 1992.					
	4.	Pica et al., "Autocrine Nerve Growth Factor is Essential for Cell Survival and Viral Maturation in HHV-8-Infected Primary Effusion Lymphoma Cells", Blood, Vol. 95, No. 9, pp. 2905-2912, May 1, 2000.					
	5.	Van Der Laan et al., "Expression of Growth Factors and Growth Factor Receptors in Normal and Tumorous Human Thyroid Tissues", Thyroid, Vol. 5, No. 1, pp. 67-73, 1995.					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: April 24, 2009